We examine how real-world evidence strategies help address uncertainties in rare disease treatments ...
Read moreAchieving HTA approval for orphan drugs requires strategic planning, early engagement, strong eviden...
Read moreIntroduction What is the secret to a successful drug launch? One crucial factor is establishing a cr...
Read moreOur latest article discusses key strategies for pharma manufacturers' commercial readiness for EU HT...
Read moreAs the focus on sustainability grows, manufacturers will need to address their products’ environme...
Read moreArticle originally published 11th August 2022, updated 18th June 2024. Introduction Digital health a...
Read moreArticle originally published 17th August 2022, updated 11th June 2024. Introduction Artificial intel...
Read moreArtificial intelligence is set to revolutionise the market access and healthcare landscape, but huma...
Read moreLearn how to navigate the upcoming EU HTA regulation and optimise market access strategies for oncol...
Read moreOur experts analyse how local European markets are integrating the EU HTA outputs into national proc...
Read more